The Ethics of Early Stopping Rules: Who Is Protecting Whom?
- 1 May 2004
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (9) , 1542-1545
- https://doi.org/10.1200/jco.2004.02.150
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup StudyJournal of Clinical Oncology, 2003
- Maintenance Therapy in Advanced Ovarian Cancer: Progression-Free Survival and Clinical BenefitJournal of Clinical Oncology, 2003
- Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group TrialJournal of Clinical Oncology, 2003
- Maybe More Is BetterJournal of Clinical Oncology, 2003
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)Journal of Clinical Oncology, 2003
- Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Interrupted versus Continuous Chemotherapy in Patients with Metastatic Breast CancerNew England Journal of Medicine, 1991